✨ Free AI Report
BeyondSpring Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research BeyondSpring Inc.
Company Research

BeyondSpring Inc.: Business Overview, Financials & Competitive Analysis

BeyondSpring is a clinical-stage biopharmaceutical company focusing on cancer therapy development through its Plinabulin pipeline and TPD (target protein degradation) platform. Recent Phase 3 DUBLIN-3 trial results sh...

Analyst-debate audio for BeyondSpring Inc.

AskCyborg analysts argue the bull and bear cases for BeyondSpring Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Clinical validation in Phase 3 NSCLC trials provides near-term value inflection potential, but cash constraints require near-term...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest BeyondSpring Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

BeyondSpring Inc. Overview

Pro stress-test →

BeyondSpring is a clinical-stage biopharmaceutical company focusing on cancer therapy development through its Plinabulin pipeline and TPD (target protein degradation) platform. Recent Phase 3 DUBLIN-3 trial results showed plinabulin plus docetaxel achieved median OS of 10.8 vs 8.8 months in Asian NSCLC patients, demonstrating clinical proof-of-concept.

Strategic Profile

Pro stress-test →

Plinabulin's mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. BeyondSpring co-founded SEED Therapeutics (38% ownership) which closed a $30M Series A-3 with FDA and NMPA IND clearance.

Competitive Landscape

Pro stress-test →

In NSCLC immunotherapy resistance space, few approved options exist despite 60% of patients developing resistance. Competitors include established checkpoint inhibitor companies (Merck, Bristol-Myers Squibb) and other IO combinations in development. BeyondSpring's dendritic cell maturation mechanism differentiates from conventional approaches.

Industry Context

BeyondSpring Inc. operates in Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation.

Key facts

Founded: 2010 · Headquarters: Florham Park, New Jersey, US

What the analysts stress-tested

The top findings that survived the multi-agent debate for BeyondSpring Inc..

  • 60% of NSCLC patients develop resistance to anti-PD-(L)1 therapy with no new treatments approved in a decade, representing significant unmet need.
  • Plinabulin markedly reduced docetaxel-induced grade 4 neutropenia (3.9% vs 26.5%), addressing a major chemo side effect.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Post-hoc DUBLIN-3 analyses showed plinabulin plus docetaxel achieved 15.8 vs 11.7 month median OS in EGFR WT NSCLC after PD-1/L1 progression
  • August 2025Q2 2025 financial results showed improved net loss of $1.9M vs $2.7M prior year; announced Med publication on plinabulin dendritic cell activation
  • +1 moreTrack every material event for BeyondSpring Inc. as it happens. Explore monitoring →
Get alerted when BeyondSpring Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Pembrolizumab + ChemotherapyPD-1 checkpoint inhibitor with docetaxel for NSCLC→Nivolumab + IpilimumabDual checkpoint inhibitor combination for cancer→DocetaxelStandard-of-care chemotherapy baseline→

Compare BeyondSpring Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BeyondSpring Inc. operates in Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation research →
NEW · MCP server

Ask your AI assistant about BeyondSpring Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BeyondSpring Inc. and its top competitor on Cyborg Score”
“What did BeyondSpring Inc. do this quarter?”
“Is BeyondSpring Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does BeyondSpring Inc. do?+
BeyondSpring is a clinical-stage biopharmaceutical company focusing on cancer therapy development through its Plinabulin pipeline and TPD (target protein degradation) platform. Recent Phase 3 DUBLIN-3 trial results sh...
What is BeyondSpring Inc.'s Cyborg Score?+
BeyondSpring Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BeyondSpring Inc.'s main competitors?+
Named competitors include Pembrolizumab + Chemotherapy, Nivolumab + Ipilimumab, Docetaxel. The full competitive landscape is in the AskCyborg report.
How can I get the full BeyondSpring Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BeyondSpring Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BeyondSpring Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score